Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 73 - 80 of 12107 results
Is Your Enantiomer Possessed?
July 15, 2025| Blog| Viewpoint
MintzTech Connect Industry News: Spotlight on Coworker.ai
July 15, 2025| Article| Viewpoint
MintzTech Connect: All Things Technology — July 2025
July 15, 2025| Article| Viewpoint
Deepfakes Face Deep Trouble: Revenge Porn in the Workplace
July 14, 2025| Blog| Viewpoint
New Jersey Adopts QSBS Exclusion: A Game-Changer for In-State Investors and Founders
July 14, 2025| Alert| Viewpoint
Utilities Slowing Development of Self-Powered Data Centers
July 13, 2025| News
Return to Real (Pre-eBay) Injunctive Relief?
July 11, 2025| Blog| Viewpoint
DOJ Issues Subpoenas Targeting Transgender Care to Minors: What Health Care Providers Need to Know
July 11, 2025| Blog| Viewpoint
News & Press Releases
SEC’s Pharmaceutical Insider Trading Case Yields Quick Deals
August 19, 2025
Bloomberg Law featured a statement from Member Jason P.W. Halperin in its coverage of a pharmaceutical insider trading case brought by the SEC. Jason and the Mintz team of Sean Prosser and Elizabeth Platonova represented Robert Yedid in reaching a resolution in which the client pled guilty and, along with the other defendants, entered into consent orders with the SEC.
Mintz Advises Oppenheimer & Co. and Initial Purchasers in $475M Convertible Senior Notes Offering by WisdomTree
August 19, 2025
Mintz represented Oppenheimer & Co., as sole book-running manager, and Craig-Hallum Capital Group and Northland Securities, as co-managers, in the private placement of $475 million aggregate principal amount of 4.625% Convertible Senior Notes due 2030 issued by WisdomTree, Inc (NYSE: WT) (“WisdomTree”). The notes were sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933.
Mintz Advises Underwriters in Assembly Biosciences' $175 Million Underwritten Offering and Concurrent Private Placement
August 18, 2025
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
Events
Podcasts
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|